Successful treatment of a patient with myelodysplastic syndrome (RAEB) with Darbepoetin-alfa in combination with Pegfilgrastim
- 2 June 2005
- journal article
- letter
- Published by Springer Nature in Annals of Hematology
- Vol. 84 (10) , 694-695
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromesBritish Journal of Haematology, 2004
- Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndromeAnnals of Hematology, 2004
- In patients with myelodysplastic syndromes response to rHuEPO and G‐CSF treatment is related to an increase of cytogenetically normal CD34+ cellsBritish Journal of Haematology, 2004
- Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trialBlood, 2004
- A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony‐stimulating factor: significant effects on quality of lifeBritish Journal of Haematology, 2003
- Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitorsBlood, 2003
- Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromesJournal of Cancer Research and Clinical Oncology, 2002
- Cytokine therapy for myelodysplastic syndromeCurrent Opinion in Hematology, 2000